Further, oncogenic BRAF fusions are frequently identified in melanomas prior to drug treatment, and BRAF fusion-positive cancers show resistance to BRAF inhibitor drugs such as vemurafenib and dabrafenib [76,77]. Here, BRAF is linked to cancer.